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SP-0387   
Does this house believe that we can avoid surgery in responder 
rectal cancer patients? For the motion 
C. Coco1, G. Rizzo1 
1Università Cattolica del Sacro Cuore, Department of Surgical 
Oncology, Rome, Italy  
  
Pathological complete response (pCR) after chemoradiation therapy 
(CRT) is increasingly reported with a range between 10% and 30%. 
Patients with pCR have been reported to have a favorable oncological 
outcome (LR 1.2% CSS 95.6%) and it rises the doubt that major surgery 
with total mesorectal excision (TME) is probably an overtreatment. 
This is specially true regarding the high rate of short and long-term 
morbidity (evacuative, urinary and sexual disfunction)  associated 
with it. The question is how to pre-operatively predict pCR with an 
high level of accuracy. Clinical complete response (cCR) is not 
homogeneusly defined and is not fully reliable in predicting pCR(25-
85%). Full-Thickness Local Excision (FTLE) after CRT in major 
responders to neoadjuvant treatment should be regarded not as a 
cancer treatment but as the best diagnostic tool to confirm pCR. The 
accuracy of FTLE in the definition of (T) it is ≈ 99% and in ypT0, 
looking at  reported series  it is possible to predict the absence of 
lymph node involvement with an accuracy of ≈ 96%. Clinical trials  to 
confirm validity of a less invasive therapeutic approach are required. 
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Radiotherapy and targeted drugs: which and how many pathway(s) 
to target? 
M. Verheij1, C. Vens2 
1The Netherlands Cancer Institute - Antoni van Leeuwenhoek 
Hospital, Radiation Oncology, Amsterdam, The Netherlands  
2The Netherlands Cancer Institute - Antoni van Leeuwenhoek 
Hospital, Biological Stress Response, Amsterdam, The Netherlands  
  
Recent insights into the molecular mechanisms underlying tumor cell 
radiosensitivity have led to the identification of a large number of 
potential targets for rational intervention. Blockade of EGFR signaling, 
interference with new blood vessel formation, and inhibition of DNA 
damage repair, are a few examples of attractive strategies to increase 
tumor response in combination with radiation (and/or chemotherapy). 
However, despite many studies on radiation-targeted drug 
combinations, the clinical benefit of these new strategies has been 
small so far. It is therefore essential to consider which possible 
mechanisms underlie this limited success. A series of studies 
demonstrated that multiple factors will have to be considered and 
point to opportunities to optimize the combination radiation-targeted 
agents. 
Focusing on a single target or signaling pathway may be an effective 
strategy for a specific tumor, but not for others. For example, 
targeted inhibition of the BRAF(V600E) oncoprotein is highly effective 
in the treatment of melanoma, but not of BRAF(V600E) mutant colon 
tumors. RNAi genetic screening revealed that blockade of EGFR 
signaling shows strong synergy with BRAF(V600E) inhibition. 
Mechanistically, BRAF(V600E) inhibition causes a rapid feedback 
activation of EGFR, explaining continued proliferation in the presence 
of BRAF(V600E) inhibition. Similarly, a feedback mechanism has been 
described in EGFR-driven cancers in which MEK inhibition leads to 
activation of PI3K/AKT signaling.Thus, targeting multiple pathways 
may be required to obtain sufficient radiosensitizing conditions. 
Normal tissue toxicity limits the therapeutic ratio of any anti-cancer 
therapy, including radiation-targeted drug combinations. A recent 
randomized phase II study at the NKI evaluating cisplatin-based 
chemoradiation with or without cetuximab in locally advanced NSCLC 
demonstrated no survival advantage, but was associated with 
significantly more grade ≥ 3 acute toxicity. 
Scheduling between radiation and targeted agents represents another 
important mechanistic aspect to take into account. This is of 
particular relevance for anti-angiogenic drugs. There are both 
preclinical and clinical data that demonstrate that treating tumors 
with this class of targeted agents is associated with a time window of 
opportunity, characterized by vessel normalization. During this phase 
of improved oxygenation and perfusion, which may differ among 
tumors, radiation (and chemotherapy) will exert their optimal anti-
tumor effect. 
Hitting the right target with a biologically optimal dose discriminates 
radiosensitization from single agent cytotoxicity. Whereas dose 
escalation studies frequently aim at identifying the maximum 
tolerated dose, radiosensitizing strategies require doses of targeted 
agents (or chemotherapy) that sufficiently modulate the predefined 
target. These doses are not necessarily associated with single agents 
dose-limiting toxicity. PARP inhibitors such as olaparib may be 
effective as radiosensitizers at significantly lower doses than required 
to exert single agent activity. It is therefore important to establish 
sensitive biomarkers that assess PARP inhibition in the context of 
radiosensitization efficacy. Such biomarkers for radio-sensitization 
efficacy of PARP inhibitors are currently evaluated in a phase I-II dose-
escalation study in locally advanced NSCLC combining olaparib with 
standard chemoradiation at the NKI. 
In summary, radiation-targeted agent combinations are attractive but 
challenging strategies that require a rational approach and careful 
study design.  
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Modern radiation oncology will require a new synergy between high-
precision radiotherapy protocols and innovative approaches for 
biological optimization of radiation effect. From a clinical 
perspective, new insight into molecular radiobiology will provide a 
unique opportunity for rational patient stratification based on 
actionable tumor targets, enabling the parallel design of next-
generation trials that formally examine the effect of adding targeted 
therapeutics to radiation, together with the critically important 
assessment of radiation dose-volume relationships of both tumor 
response and normal tissue toxicity. In considering the use of systemic 
agents with presumed radiosensitizing activity, this will need 
particular attention in defining patient eligibility. The presentation 
will highlight principles in addressing clinical evaluation of combined-
modality targeted therapeutics and radiotherapy. 
Omes – Pathways to be targeted: On review of 90 recent early-phase 
trials combining targeted therapeutics and radiation, a number of 
actionable tumor signaling pathways involved in tumor proliferation, 
angiogenesis, and hypoxia were found to have been examined, with 
tolerability, safety, and efficacy as study endpoints. In these trials, 
treatment outcome was diverse, ranging from tolerable to significant 
toxicities, and from lack of additional via significant responses to 
unexpected early disease progression. Our review did not specifically 
investigate whether the systemic agents had been evaluated with 
respect to biological mechanisms of radiosensitization in appropriate 
preclinical tumor models prior to the specific clinical studies. 
Omics – Procedures for identifying relevant actionable targets: In 
medical oncology early-phase studies of systemic targeted 
therapeutics, the prevailing gold-standard for patient selection is 
based primarily on the detection of tumor gene aberrations. In 
contrast, in radiotherapy, the composite activities of a range of 
signaling effector proteins determining tumor resistance to radiation 
may conceptually comprise a functional biomarker of actionable 
targets for radiosensitization. Hence, theranostic profiling 
technologies should ideally reflect all interacting signaling pathways 
involved in tumor proliferation, angiogenesis, and hypoxia. Using array 
technology with tyrosine kinase substrates, we have shown that 
composite tumor signaling mediated by high phosphatidylinositol-3-
kinase activity may be a biomarker for treatment stratification in 
rectal cancer patients undergoing neoadjuvant chemoradiotherapy. 
Optimization – Patient eligibility: Treatment protocols should 
minimize the specific detriment of interruption in radiation delivery 
and the consequent negative impact on the probability of tumor 
control. Hence, only patients that are not candidates for curative 
radiotherapy protocols should be regarded as eligible in a trial setting 
of evaluating tolerability of a first-in-human combination of radiation 
with a targeted therapeutic. Of note, in our investigation of recent 
early-phase combined-modality trials, one-third of studies with 
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curative (definitive or preoperative) therapeutic intent reported 
significant toxicity. To enable full interpretation of outcome toxicity 
data, both the specific tumor type and the related disease site being 
irradiated will require both to be specified as study eligibility criteria, 
together with a description of detailed radiation dose-volume 
dependencies within the treatment protocol. This will also facilitate 
identification of adverse radiation effects that are separate from toxic 
effects of the systemic agent. In addition to determining treatment 
safety, proof of biological activity and – ideally – target-dependent 
radiosensitizing ability of the investigational agent should be regarded 
as a study objective. Finally, if the study eligibility criteria employ 
the principles of defining both the tumor type and anatomic location 
of the specific target volume being treated, the resultant 
homogeneous patient population will also ultimately enable treatment 
response evaluation. 
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Taxonomies for synoptic reporting and analysis of radiation 
treatment incidents 
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Synoptic reporting and analysis of incidents in radiotherapy, and 
elsewhere in medicine, means being directed to providing key 
descriptive information in a structured format. There are three 
principal advantages of synoptic reporting: completeness, lack of 
ambiguity and searchability. Firstly, the reporting and analysis forms, 
if well designed, will ensure that all key information required to 
understand the incident and to develop corrective actions is recorded. 
This meets the requirement of completeness. The problem of 
ambiguity can, to some extent, be mitigated by restricting responses 
to key elements of the report and analysis to predetermined lists of 
options with carefully thought out language. The third benefit of 
structured synoptic reporting is that the databases into which reports 
and analyses are entered can be rapidly searched and hence major 
issues flagged and trends identified. Additional flexibility is included 
in an incident learning system through incorporating free text boxes 
where the reporter and analyst can augment the basic information 
entered. 
The presentation will commence with an overview of a generic 
incident learning system and will then introduce SAFRON and the U.S. 
national incident reporting initiative as examples of the 
implementation of such systems. The structure of these will be 
discussed identifying the synoptic and free text components. To 
understand where in the radiotherapy process the incident originated 
and where it was discovered process maps are used. The severity of 
an incident, which often determines the priority of the response and 
corrective actions, is an important component of the synopsis 
although severity can be hard to establish particularly as the 
consequences of a clinical RT incident may not be apparent for weeks 
or months. In order to implement effective corrective actions it is 
important that they follow from the identification of basic 
causes/contributing factors. The approaches of SAFRON and the U.S. 
implementation will be discussed in the context of these three 
synoptic elements. 
As well as enhancing the quality and safety of radiotherapy, properly 
constructed incident learning systems can also help us to identify the 
most effective impediments to error propagation. Both SAFRON and 
the US system specifically include safety barriers in the synoptic 
reporting structure. The reporter/analyst is invited to identify those 
barriers which the error penetrated and that barrier at which the 
error was stopped. 
Synoptic reporting aids clear communication and analysis of 
radiotherapy incidents. It can also guide the development of an 
efficient safety program by discriminating between more effective 
and less effective safety barriers. 
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The patient experience as a catalyst for change 
M. Murphy1 
1WHO, Patients for Patient Safety Programme, Cork City, Ireland 
Republic of  
 
Following the death of her son as a result of medical error, the 
focusof Margaret’s work relates to seeing adverse events as having the 
potential tobe catalysts for change as well as being opportunities for 
learning, identifying areas for improvement and preventing 
recurrence.  
During her presentation she will provide a case study highlighting the 
gaps between the patient safety measures possible and those actually 
being experienced by patients (communication, record-keeping, 
diagnosis and test results, handovers, transitions in care, responding 
to the deteriorating patient, practising truly patient centred care). 
She will also discuss: 
· The case for involvement of patient and family in assuring safe care. 
· The need to demonstrate professionalism in the aftermath of 
adverse events – transparency, disclosure, learning and preventing 
recurrence. 
· The patient experience of care and the students’ response to being 
exposed to that reality - the power of the story. 
· The role of education in creating sustainableculture change. 
She will offer some reflections on nuclear medicine from a patient 
perspective and propose the WHO Patients for Patient Safety 
collaborative/partnership model as a patient safety solution. 
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Quality indicators and standards in radiotherapy contouring 
G.C. Mattiucci1 
1Università Cattolica del Sacro Cuore, Radiation Oncology, Roma, 
Italy  
  
Purpose: This lecture will present the actual scenario of contouring 
standards in Radiotherapy and how a correct segmentation of target 
and organs at risk grant a reliable treatment plan.  An overview of all 
the anatomical districts will be offered together with a deepening in 
the delineation quality indicators, defined as contours adherence to 
International or Institutional Guidelines. 
Method and materials: Different techniques and technologies such as 
high definition morpho/biological imaging, contouring atlases with or 
without tutorial purposes, different rigid and deformable 
commercially available coregistration softwares with autocontouring 
features have been presented in order to explore their role in gaining 
adequate standards in contouring procedures.  
A brief overview of the main similarity indexes has been offered too. 
Results: An adequate quality assurance in contouring is mandatory to 
grant a reliable treatment plan: in order to check the adherence of 
contours proposed by a manual delineator or by an autosegmentation 
software to adopted guidelines indexes, such as the Dice Similarity 
Index can be calculated, also for tutorial purposes. 
Conclusions: Modern Radiotherapy (RT) can deliver high dose rates to 
extremely small volumes and high precision RT could mean significant 
dosimetrical error due to a unfitting dose coverage or to a systemic 
error caused by inappropriate contouring.  
Modern technologies can help in maintaining adequate contouring 
standards but an Indipendet Check (IC) by skilled operators of the 
proposed structures remains mandatory. 
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Accidents and near misses in radiotherapy delivery, and the 
ACCIRAD project 
J. Godet1 
1ASN France, Radiation Oncology, Paris, France  
  
Serious radiotherapy accidents have been notified in France in 2005 
and 2006 (Epinal, Toulouse). The main identified causes were 
organisational and human factors. In response, a national action plan, 
later part of the national cancer plan 2009-2013, was implemented by 
the Health Ministry between 2007 and 2012. INCa (French National 
Cancer Institute) was in charge of managing the national action plan 
which involved several stakeholders, including radiation oncologist 
and medical physicist societies.The national action plan was based on 
33 national measures spread across seven fields as the quality and 
safety of the practices, the vigilance in radiotherapy, the human 
resources and training, the safety of facilities, the relationship with 
patients and the public, the strengthening of ASN’s inspections and 
the monitoring and knowledge of the discipline. In addition to  its 
inspection program, ASN has led 3 national radiotherapy measures : 
 publication of a set of radiotherapy quality requirements and a 
strengthening of the regulations specifying the quality assurance 
(QA) obligations, including risk analysis ;  
 publishing of guidelines for professionals on the notification of 
significant radiation protection events (SRPE) ;  
 creation of an incident scale rating for the purposes of 
communicating to the public.  
Since 2008, each year, ASN publishes the main findings of its 
inspection program in radiotherapy, stressing on the progressive 
improvement of safety treatments. Reports on SRPE, presenting the 
main causes of the events, are also put on ASN website. The increase 
of the number of notified events since 2008 demonstrates the 
improvement of safety culture, most of notified events being without 
any consequences to the health of patients. The feedback experience 
